SCHEMBL20122797

SCHEMBL20122797

COc1ccc(-c2cc(Cl)cc3c2[nH]c2c(C)nccc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 9/20 0.54
DYRK1A Q13627 7/20 0.54
KDM4E B2RXH2 1/20 0.54
DYRK3 O43781 1/20 0.54
CCNT1 O60563 1/20 0.54
CCNB2 O95067 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CYP1A2 P05177 1/20 0.54
CDK1 P06493 1/20 0.54
CYP3A4 P08684 1/20 0.54
ADRA2A P08913 1/20 0.54
CYP2D6 P10635 1/20 0.54
CCNB1 P14635 1/20 0.54
HPGD P15428 1/20 0.54
ADRA2B P18089 1/20 0.54
ADRA2C P18825 1/20 0.54
CCNA2 P20248 1/20 0.54
ACHE P22303 1/20 0.54
SLC6A2 P23975 1/20 0.54
CDK2 P24941 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756312 1.00 MAOA (0.54) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL30664335 0.89 MAOA (0.43) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL20122834 0.89 MAOA (0.43) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL20122951 0.88 MAOA (0.47) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL30664264 0.88 MAOA (0.47) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL20122962 0.88 MAOA (0.56) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL30664258 0.87 MAOA (0.42) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL20123012 0.87 MAOA (0.42) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL30664265 0.87 MAOA (0.45) MAOADYRK1AKDM4EDYRK3CCNT1
SCHEMBL20123036 0.87 MAOA (0.45) MAOADYRK1AKDM4EDYRK3CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN claimed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP claimed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885DYRK1A 493/4885KDM4E 706/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885DYRK1A 493/4885KDM4E 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.